Nintedanib is a multi-targeted tyrosine kinase inhibitor, often described as a triple angiokinase because it blocks VEGFR1-3, PDGFR alpha and beta, and FGFR1-3, with additional activity against CSF1R, FLT3 and Src-family kinases. Although it is sometimes grouped with immunotherapy in commercial listings, it is mechanistically a kinase inhibitor with anti-angiogenic and antifibrotic activity, used in non-small cell lung cancer and progressive fibrotic lung disease. For procurement teams, the sourcing challenges are formulation stability and predictable supply rather than cold chain.
Nintedanib is supplied as soft gelatin capsules, commonly in 100 mg and 150 mg strengths, taken with food. Soft capsules are sensitive to moisture and should be stored at room temperature in tight, original containers away from humidity and excess heat. They do not require refrigerated transport, but humidity-controlled warehousing protects capsule integrity and shelf life. Because nintedanib is a substrate of P-glycoprotein, storage and handling practices that preserve the dosage form also protect therapeutic consistency across batches.
Planning should match pack sizes and MOQ to realistic clinical demand, since oncology and ILD volumes differ by market. Confirm batch release timing and Certificate of Analysis availability before committing, and align lead times with the product's expiry horizon so stock is not written off. Essential documentation mirrors other prescription kinase inhibitors: GMP certificate, batch CoA, and registration or import permit for the destination. Verifying the exact strength and brand on the authorization record prevents costly mis-shipments.
Specification discipline protects patients and margins alike. Confirming the exact strength and brand on the authorization record, and matching it to the physical pack, prevents the mis-shipments that are costly to recall and damaging to trust. Because soft capsules are moisture-sensitive, transit humidity and warehouse conditions should be part of the supplier agreement, not an afterthought. Distributors who invest in humidity-controlled storage and clear batch documentation position themselves as reliable partners for the specialist clinics and ILD centers that account for most nintedanib demand. Regular review of expiry horizons against reorder volume keeps slow-moving specialty stock from aging out before it reaches the patient, and that discipline is what separates a dependable oncology supplier from a transactional one.
Q: Is nintedanib an immunotherapy? A: No. Despite some commercial labels, nintedanib is a multi-targeted tyrosine kinase inhibitor with anti-angiogenic and antifibrotic activity, not an immune checkpoint agent.
Q: Does nintedanib need refrigerated transport? A: No. It is stored at room temperature in moisture-protected original packaging; humidity control is the main stability concern.
Q: Which documents support compliant sourcing? A: A batch Certificate of Analysis, a GMP certificate, and a valid registration or import permit for the destination market are the standard requirements.
Nintedanib is a multi-targeted tyrosine kinase inhibitor, often described as a triple angiokinase because it blocks VEGFR1-3, PDGFR alpha and beta, and FGFR1-3, with additional activity against CSF1R, FLT3 and Src-family kinases. Although it is sometimes grouped with immunotherapy in commercial listings, it is mechanistically a kinase inhibitor with anti-angiogenic and antifibrotic activity, used in non-small cell lung cancer and progressive fibrotic lung disease. For procurement teams, the sourcing challenges are formulation stability and predictable supply rather than cold chain.
Nintedanib is supplied as soft gelatin capsules, commonly in 100 mg and 150 mg strengths, taken with food. Soft capsules are sensitive to moisture and should be stored at room temperature in tight, original containers away from humidity and excess heat. They do not require refrigerated transport, but humidity-controlled warehousing protects capsule integrity and shelf life. Because nintedanib is a substrate of P-glycoprotein, storage and handling practices that preserve the dosage form also protect therapeutic consistency across batches.
Planning should match pack sizes and MOQ to realistic clinical demand, since oncology and ILD volumes differ by market. Confirm batch release timing and Certificate of Analysis availability before committing, and align lead times with the product's expiry horizon so stock is not written off. Essential documentation mirrors other prescription kinase inhibitors: GMP certificate, batch CoA, and registration or import permit for the destination. Verifying the exact strength and brand on the authorization record prevents costly mis-shipments.
Specification discipline protects patients and margins alike. Confirming the exact strength and brand on the authorization record, and matching it to the physical pack, prevents the mis-shipments that are costly to recall and damaging to trust. Because soft capsules are moisture-sensitive, transit humidity and warehouse conditions should be part of the supplier agreement, not an afterthought. Distributors who invest in humidity-controlled storage and clear batch documentation position themselves as reliable partners for the specialist clinics and ILD centers that account for most nintedanib demand. Regular review of expiry horizons against reorder volume keeps slow-moving specialty stock from aging out before it reaches the patient, and that discipline is what separates a dependable oncology supplier from a transactional one.
Q: Is nintedanib an immunotherapy? A: No. Despite some commercial labels, nintedanib is a multi-targeted tyrosine kinase inhibitor with anti-angiogenic and antifibrotic activity, not an immune checkpoint agent.
Q: Does nintedanib need refrigerated transport? A: No. It is stored at room temperature in moisture-protected original packaging; humidity control is the main stability concern.
Q: Which documents support compliant sourcing? A: A batch Certificate of Analysis, a GMP certificate, and a valid registration or import permit for the destination market are the standard requirements.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
